Skip to content

Three-Point Paravertebral Block for Uniportal VATS Analgesia

Analgesic Efficacy of Paravertebral Nerve Block with Liposomal Bupivacaine Using the Three-Point Technique After Uniportal Video-Assisted Thoracoscopic Surgery

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2600127290
Enrollment
Unknown
Registered
2026-06-29
Start date
2026-06-30
Completion date
Unknown
Last updated
2026-07-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Postoperative pain after uniportal thoracoscopic surgery

Interventions

Control group:Ultrasound-guided paravertebral nerve block at T3–T7 levels was performed with 20 mL of liposomal bupivacaine (266 mg in total).
Experimental group A:Under direct thoracoscopic vision, three-point intercostal nerve block with liposomal bupivacaine (266mg/20 mL per vial) was performed at the 3rd, 4th, and 5th intercostal spaces
Experimental group B:On the basis of experimental group A, ultrasound-guided paravertebral nerve block at the T3–T7 level was added, using 20 mL of liposomal bupivacaine, 133 mg in total. A total of 2

Sponsors

Zhejiang Cancer Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Aged 18–75 years; 2. Scheduled to undergo unilateral lobectomy, segmentectomy or wedge resection via uniportal video-assisted thoracoscopic surgery (VATS); 3. ASA physical status classification Grade ?–?; 4. Signed informed consent preoperatively.

Exclusion criteria

Exclusion criteria: 1. Severe cardiopulmonary dysfunction (e.g., FEV1 < 40% of predicted value, NYHA class III–IV); 2. History of previous thoracic surgery resulting in abnormal anatomical structures; 3. Known hypersensitivity to bupivacaine or components of the liposomal formulation; 4. Presence of coagulation disorders or use of anticoagulants (anticoagulants must be discontinued until within a safe range); 5. Contraindications to paravertebral puncture (e.g., infection, spinal deformity, neurological diseases, etc.); 6. Inability to cooperate with pain assessment or communication disorders.

Design outcomes

Primary

MeasureTime frame
Dynamic and static pain scores at 24 hours postoperatively;

Secondary

MeasureTime frame
Surgical Procedure & Operative Time;Dynamic and static pain scores at 12 and 48 hours postoperatively.;Time to discharge;Extubation time;Postoperative complications;Opioid consumption (fentanyl equivalents);Location and Character of Pain;

Countries

China

Contacts

Public ContactJian Zeng

Zhejiang Cancer Hospital

68640770@qq.com+86 571 88128101

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Jul 23, 2026